{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-057066","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.142364+00:00","generated_at":"2026-05-19T19:00:49.989404+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Celldex shareholders approve equity plan increase, elect directors including Denice Torres","bullets":["Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.","All 9 director nominees elected, including new director Denice Torres; Karen Shoos' term ended.","Ratification of PricewaterhouseCoopers as auditor for FY2025: 58M for, 119K against.","Advisory say-on-pay approved: 53.5M for, 627K against.","Harry Penner elected Chair of board post-meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-057066","json":"https://secwatch.observer/filing/0001104659-25-057066.json","markdown":"https://secwatch.observer/filing/0001104659-25-057066.md","text":"https://secwatch.observer/filing/0001104659-25-057066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000110465925057066/0001104659-25-057066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000110465925057066/tm2517205d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T19:00:49.989404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}